目的 探讨心悦胶囊联合非洛地平治疗冠心病心绞痛的疗效。方法 选取2019年6月—2020年6月在河南中医药大学第一附属医院进行治疗的66例冠心病心绞痛患者，根据住院的先后顺序分为对照组和治疗组，每组各33例。对照组口服非洛地平缓释片，5 mg次，1次/d。治疗组在对照组治疗基础上口服心悦胶囊，0.6 g/次，3次/d。两组患者均治疗12周。观察两组的临床疗效，比较两组相关评分、心功能指标和血清学指标的变化情况。结果 经治疗，治疗组心绞痛症状疗效总有效率是96.97%，显著高于对照组的81.82%（P<0.05）；治疗组心电图疗效是96.97%，显著高于对照组的84.85%（P<0.05）。经治疗，两组西雅图心绞痛量表（SAQ）评分、WHOQOL-BREF评分、自我效能感量表（GSES）评分均较治疗前显著升高，但GRACE评分显著降低（P<0.05）；治疗后，治疗组相关量表评分改善优于对照组（P<0.05）。经治疗，两组心脏指数（CI）、E峰流速/A峰流速（E/A）、心排血量（CO）均显著升高（P<0.05），且治疗后治疗组心功能改善更明显（P<0.05）。经治疗，两组血清组织内转化生长因子β结合蛋白2（LTBP2）、白三烯B4（LTB4）、白细胞介素-18（IL-18）、心肌营养素1（CT-1）、中性粒细胞明胶酶相关载脂蛋白（NGAL）水平均显著降低（P<0.05）；且治疗后治疗组患者血清学指标低于对照组（P<0.05）。结论 心悦胶囊联合非洛地平治疗冠心病心绞痛可有效改善患者症状，促进患者心功能及血清细胞因子水平的改善，有利于提高患者生存质量，有良好的临床应用价值。

Objective To explore the effect of Xinyue Capsules combined with felodipine in treatment of coronary heart disease angina pectoris.Methods A total of 66 patients with coronary heart disease angina pectoris who were treated in the First Affiliated Hospital of Henan University of CM from June 2019 to June 2020 were selected and divided into control group and treatment group according to the order of hospitalization, with 33 patients in each group. Patients in the control group were po administered with Felodipine Sustained Release Tablets, 5 mg/time, once daily. Patients in the treatment group were po administered with Xinyue Capsules on the basis of the control group, 0.6 g/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the changes of related scores, cardiac function indexes and serological indexes were compared between the two groups.Results After treatment, the total effective rate of angina symptom in treatment group was 96.97%, which was significantly higher than that of control group (81.82%,P<0.05). The ECG efficacy of the treatment group was 96.97%, which was significantly higher than that of the control group (84.85%,P<0.05). After treatment, Seattle Angina Scale (SAQ) score, WHOQOL-BREF score and self-efficacy scale (GSES) score were significantly increased, but GRACE score was significantly decreased (P<0.05). After treatment, the improvement of related scale scores in treatment group was better than that in control group After treatment, cardiac index (CI), peak velocity of E/A (E/A), and cardiac output (CO) were significantly increased in both groups (P<0.05), and cardiac function was improved more significantly in the treatment group after treatment (P<0.05). After treatment, the levels of transforming growth factor β-binding protein 2 (LTBP2), leukotriene B4 (LTB4), interleukin-18 (IL-18), cardiomyutrient 1 (CT-1), and neutrophil gelatase-associated apolipoprotein (NGAL) in serum were significantly decreased in both groups (P<0.05). After treatment, the serum indexes in the treatment group were lower than those in the control group (P<0.05).Conclusion Xinyue Capsules combined with felodipine can effectively improve the symptoms of patients in treatment of coronary heart disease angina pectoris, and can promote the improvement of cardiac function and serum cytokine levels, and is conducive to improve the life quality of patients, which has a good clinical application value.

R972

河南省中医药科学研究专项课题（2016ZY3003）